• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Revealing the mechanism of treatment resistance of cancer stem cells.

Research Project

Project/Area Number 26861074
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeMulti-year Fund
Research Field Digestive surgery
Research InstitutionOsaka University

Principal Investigator

Miyake Yuichirou  大阪大学, 医学部附属病院, 医員 (80724260)

Project Period (FY) 2014-04-01 – 2016-03-31
Project Status Completed (Fiscal Year 2015)
Budget Amount *help
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Keywordscancer stem cell / low proteasome activity / treatment resistance / 癌幹細胞 / 低プロテアソーム活性 / 抗癌剤治療抵抗性 / 放射線治療抵抗性
Outline of Final Research Achievements

Detection and isolation of cancer cells with low proteasome activity were successfully done by using virus vector which could label the cells with low proteasome activity. Then cancer stemness of these low proteasome activity cells was confirmed by up-regulation of sphere formation ability, increased treatment resistance, and highly expressed cancer stem cell markers.
After the confirmation of cancer stemness of cells with low proteasome activity, to reveal the mechanism of acquisition of cancer stemness by low proteasome activity, microarray analysis was performed. In the cells with low proteasome activity, expression of several genes were up-regulated (e.g., MMP-1, EID3). Especially EID3 was significant prognostic factor for the patients with colorectal cancer. Our data indicated that EID3 promotes the growth of cancer cells, and relates the treatment resistance.

Report

(3 results)
  • 2015 Annual Research Report   Final Research Report ( PDF )
  • 2014 Research-status Report
  • Research Products

    (2 results)

All 2014

All Journal Article (2 results) (of which Peer Reviewed: 2 results)

  • [Journal Article] Decreased miR-340 expression in bone marrow is associated with liver metastasis of colorectal cancer.2014

    • Author(s)
      Takeyama H, Yamamoto H, Yamashita S, Wu X, Takahashi H, Nishimura J, Haraguchi N, Miyake Y, Suzuki R, Murata K, Ohue M, Kato T, Takemasa I, Mizushima T, Ishii H, Mimori K, Doki Y, Mori M.
    • Journal Title

      Mol Cancer Ther.

      Volume: 13(4) Issue: 4 Pages: 976-985

    • DOI

      10.1158/1535-7163.mct-13-0571

    • Related Report
      2014 Research-status Report
    • Peer Reviewed
  • [Journal Article] Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer.2014

    • Author(s)
      Hasegawa J, Nishimura J, Mizushima T, Miyake Y, Kim HM, Takemoto H, Tamagawa H, Noura S, Fujii M, Fujie Y, Kato T, Miwa H, Takemasa I, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M.
    • Journal Title

      Cancer Chemother Pharmacol

      Volume: 73(5) Issue: 5 Pages: 1079-1087

    • DOI

      10.1007/s00280-014-2417-9

    • Related Report
      2014 Research-status Report
    • Peer Reviewed

URL: 

Published: 2014-04-04   Modified: 2017-05-10  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi